

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GLOBAL BIO-CHEM TECHNOLOGY GROUP COMPANY LIMITED

大成生化科技集團有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00809)

VOLUNTARY ANNOUNCEMENT – BUSINESS UPDATE

COOPERATION WITH SHENZHOU BIO-TECH ON PRODUCTION OF COENZYME Q10 MYCELIUM

This announcement is made by Global Bio-chem Technology Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) on a voluntary basis to keep shareholders and potential investors of the Company informed of the latest development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that 長春大成大合生物技術開發有限公司 (Changchun Dacheng Dahe Bio-tech Development Co., Ltd.*) (“**Dacheng Dahe**”), an indirect wholly-owned subsidiary of the Company, entered into a cooperation agreement (the “**Cooperation Agreement**”) with 神州生物科技有限責任公司 (Shenzhou Bio-tech Co., Ltd.*) (“**Shenzhou Bio-tech**”), pursuant to which Shenzhou Bio-tech agreed to engage Dacheng Dahe for the production of coenzyme Q10 mycelium.

Under the Cooperation Agreement, Shenzhou Bio-tech shall provide its proprietary strains and the relevant technologies and support, including parameters for processing, to Dacheng Dahe for its production of coenzyme Q10 mycelium in accordance with Shenzhou Bio-tech’s instructions, and Dacheng Dahe shall carry out production feasibility assessments and upgrade its production facilities to ensure that the expected production volume can be met. It is also agreed that upon satisfactory product inspection by Shenzhou Bio-tech, Shenzhou Bio-tech would procure from Dacheng Dahe coenzyme Q10 mycelium in accordance with the monthly procurement plan of Shenzhou Bio-tech, with a minimum purchase volume of 1,270 metric tonnes of coenzyme Q10 for the period from 1 January 2027 to 31 December 2028.

To the best of the knowledge, information and belief of the Directors having made all reasonable enquiries, Shenzhou Bio-tech is a company established in the People's Republic of China (the "PRC") specialising in the field of biological fermentation, with approximately 50.1% of its equity interest held by China Resources Double-Crane Pharmaceutical Co., Ltd. 華潤雙鶴藥業股份有限公司 ("CR Double-Crane"), a PRC company listed on the Shanghai Stock Exchange (Stock Code: SH.600062) with a principal business of manufacturing and wholesale of pharmaceutical products. CR Double-Crane is indirectly owned as to approximately 60.2% by China Resources Pharmaceutical Group Limited, a leading integrated pharmaceutical company established in Hong Kong which has a state-owned background and whose shares are listed on The Stock Exchange of Hong Kong (Stock Code: 3320).

The Board considers that the cooperation with Shenzhou Bio-tech will enable the Group to explore new markets and enhance its production techniques and efficiency. The entering into of the Cooperation Agreement also provides valuable opportunities for the Group to expedite its business development and increase brand awareness in the PRC through collaboration with large enterprise with state-owned background. As such, the Board is of the view that the Cooperation Agreement and the transactions contemplated thereunder, are in line with the Group's long-term development objectives and are in the interest of the Group and its shareholders as a whole.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company. Further announcement(s) will be made by the Company as and when appropriate in accordance with the Listing Rules.

By order of the Board
Global Bio-chem Technology Group Company Limited
Wang Cheng
Chairman

Hong Kong, 8 May 2026

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Wang Cheng and Mr. Wang Guicheng; one non-executive Director, namely, Mr. Li Yüewen; and three independent non-executive Directors, namely, Ms. Jiang Fangfang, Mr. Tan Chao and Ms. Xie Liangqiu.

** For identification purposes only*